When things seem too good to be true on Wall Street, they usually are.
It's that time of year again. I'm not referring to buying gifts and preparing holiday meals -- although that may be part of your agenda too. It's time to look back on your portfolio's performance and plan...
This week, Pfizer PFE issued its financial guidance for 2025. Sanofi SNY and Teva Pharmaceutical’s TEVA inflammatory bowel disease (IBD) study on their candidate, duvakitug (TEV’574), met its primary...
Let’s take a look at Barchart’s Bear Call Spread Screener for December 19th:
Shares of Pfizer (NYSE: PFE) recently marched higher in response to a dividend payout raise and a forward-looking presentation. Management confirmed the annual revenue and earnings outlook it provided...
Some analysts are optimistic about Pfizer’s potential for growth, especially considering its focus on oncology and recent strategic acquisitions.
Merck MRK announced that the FDA has accepted the biologics license application (BLA) for its investigational prophylactic long-acting monoclonal antibody, clesrovimab (MK-1654), designed to protect infants...
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:NVS),(NYSE:PFE),(NYSE:GSK),(NYSE:BMY) EQNX::TICKER_END
December S&P 500 E-Mini futures (ESZ24) are up +0.22%, and December Nasdaq 100 E-Mini futures (NQZ24) are up +0.26% this morning as investors looked ahead to the Federal Reserve’s final policy decision...
These top-tier income stocks are sporting an average yield of 8.53%!